Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1939 1
1949 1
1963 1
1972 1
1974 2
1975 1
1976 1
1981 2
1982 1
1984 1
1985 1
1986 3
1987 8
1988 10
1989 12
1990 7
1991 12
1992 9
1993 7
1994 9
1995 17
1996 15
1997 17
1998 7
1999 16
2000 16
2001 15
2002 10
2003 12
2004 18
2005 11
2006 15
2007 25
2008 15
2009 9
2010 9
2011 7
2012 7
2013 5
2014 4
2015 5
2016 8
2017 4
2018 6
2019 4
2020 8
2021 11
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

365 results

Results by year

Filters applied: . Clear all
Page 1
Molecular classification of hormone receptor-positive HER2-negative breast cancer.
Jin X, Zhou YF, Ma D, Zhao S, Lin CJ, Xiao Y, Fu T, Liu CL, Chen YY, Xiao WX, Liu YQ, Chen QW, Yu Y, Shi LM, Shi JX, Huang W, Robertson JFR, Jiang YZ, Shao ZM. Jin X, et al. Among authors: robertson jfr. Nat Genet. 2023 Oct;55(10):1696-1708. doi: 10.1038/s41588-023-01507-7. Epub 2023 Sep 28. Nat Genet. 2023. PMID: 37770634
Covid-19 in the workplace.
Agius RM, Robertson JFR, Kendrick D, Sewell HF, Stewart M, McKee M. Agius RM, et al. Among authors: robertson jfr. BMJ. 2020 Sep 21;370:m3577. doi: 10.1136/bmj.m3577. BMJ. 2020. PMID: 32958470 No abstract available.
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Robertson JFR, et al. Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29. Lancet. 2016. PMID: 27908454 Clinical Trial.
Fulvestrant.
Cheung KL, Robertson JF. Cheung KL, et al. Among authors: robertson jf. Expert Opin Investig Drugs. 2002 Feb;11(2):303-8. doi: 10.1517/13543784.11.2.303. Expert Opin Investig Drugs. 2002. PMID: 11829719 Review.
Fulvestrant: pharmacokinetics and pharmacology.
Robertson JF, Harrison M. Robertson JF, et al. Br J Cancer. 2004 Mar;90 Suppl 1(Suppl 1):S7-10. doi: 10.1038/sj.bjc.6601630. Br J Cancer. 2004. PMID: 15094758 Free PMC article. Review.
Granulomatous lobular mastitis.
Galea MH, Robertson JF, Ellis IO, Elston CW, Blamey RW. Galea MH, et al. Among authors: robertson jf. Aust N Z J Surg. 1989 Jul;59(7):547-50. doi: 10.1111/j.1445-2197.1989.tb01629.x. Aust N Z J Surg. 1989. PMID: 2665711 Review.
A good drug made better: the fulvestrant dose-response story.
Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM. Robertson JF, et al. Clin Breast Cancer. 2014 Dec;14(6):381-9. doi: 10.1016/j.clbc.2014.06.005. Epub 2014 Jun 24. Clin Breast Cancer. 2014. PMID: 25457991 Review.
c-erbB-2 expression in primary breast cancer.
Tagliabue E, Ménard S, Robertson JF, Harris L. Tagliabue E, et al. Among authors: robertson jf. Int J Biol Markers. 1999 Jan-Mar;14(1):16-26. doi: 10.1177/172460089901400104. Int J Biol Markers. 1999. PMID: 10367245 Free article. Review.
Preoperative endocrine therapy for breast cancer.
Cheung KL, Howell A, Robertson JF. Cheung KL, et al. Among authors: robertson jf. Endocr Relat Cancer. 2000 Sep;7(3):131-41. doi: 10.1677/erc.0.0070131. Endocr Relat Cancer. 2000. PMID: 11021962 Review.
365 results